A Phase IIIB, Open-Label, Randomized, Multi-Center Study Evaluating the Effect on Serum Lipids Following a Switch to ATV/r [atazanavir + ritonavir] in in HIV-1 Infected Subjects Who Have Achieved Virologic Suppression on a LPV/r [lopinavir/ritonavir] Based Regimen.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Atazanavir (Primary) ; Lopinavir; Ritonavir
- Indications HIV-1 infections
- Focus Adverse reactions
- 14 Jul 2009 Actual end date changed from Oct 2005 to May 2006 as reported by ClinicalTrials.gov.
- 15 Nov 2005 New trial record.